Jefferies Group LLC reaffirmed their buy rating on shares of Zoetis Inc. (NYSE:ZTS) in a research report sent to investors on Friday morning. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.

ZTS has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $71.00 price target on the stock in a research note on Thursday, October 12th. Cantor Fitzgerald reiterated a buy rating and issued a $75.00 price target on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a hold rating to a sell rating in a research note on Friday, October 6th. Morgan Stanley upped their price target on shares of Zoetis from $61.00 to $70.00 and gave the stock an equal weight rating in a research note on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) reiterated a neutral rating and issued a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis currently has a consensus rating of Buy and an average target price of $67.06.

Shares of Zoetis (NYSE ZTS) opened at $69.13 on Friday. The firm has a market cap of $33,686.22, a PE ratio of 31.71, a PEG ratio of 2.02 and a beta of 1.02. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a 1 year low of $48.24 and a 1 year high of $70.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. Zoetis’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.52 EPS. research analysts anticipate that Zoetis will post 2.36 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Zoetis Inc. (ZTS) Earns “Buy” Rating from Jefferies Group LLC” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/zoetis-inc-zts-earns-buy-rating-from-jefferies-group-llc/1699272.html.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a yield of 0.61%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio is currently 22.11%.

Several large investors have recently modified their holdings of ZTS. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the period. Harfst & Associates Inc. lifted its stake in shares of Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the period. Almanack Investment Partners LLC. bought a new position in shares of Zoetis in the 2nd quarter worth approximately $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the period. Finally, Peddock Capital Advisors LLC bought a new position in shares of Zoetis in the 2nd quarter worth approximately $140,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.